



(12) Translation of
European patent specification

(11) NO/EP 3652178 B1

NORWAY


(19) NO
(51) Int Cl.
C07D 487/04 (2006.01)
A61K 31/41 (2006.01)
A61K 31/437 (2006.01)
A61K 31/5365 (2006.01)
A61P 25/16 (2006.01)
A61P 25/28 (2006.01)
C07D 498/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.03.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.01.24
(86)	European Application Nr.	18740815.8
(86)	European Filing Date	2018.07.12
(87)	The European Application's Publication Date	2020.05.20
(30)	Priority	2017.07.14, US, 201762532767 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Validation States:	MA
(73)	Proprietor	F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Sveits
(72)	Inventor	PATEL, Snahel, c/o Genentech Inc. 1 DNA Way, South San Francisco, CA 94080, USA HAMILTON, Gregory, c/o Genentech Inc. 1 DNA Way, South San Francisco, California 94080, USA ZHAO, Guiling, c/o Genentech Inc. 1 DNA Way, South San Francisco, California 94080, USA CHEN, Huifen, c/o Genentech Inc. 1 DNA Way, South San Francisco, California 94080, USA DANIELS, Blake, c/o Genentech Inc. 1 DNA Way, South San Francisco, California 94080, USA STIVALA, Craig, c/o Genentech Inc. 1 DNA Way, South San Francisco, California 94080, USA
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, C. J. Hambros plass 2, 0164 OSLO, Norge

(54)	Title	BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF
(56)	References Cited:	WO-A1-2019/072942 WO-A1-2014/125444

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


PATENTKRAV**1.** Forbindelse med formel (1):


eller et farmasøytisk akseptabelt salt derav, hvor:

R^1 er valgt fra gruppen som består av C_1 - C_6 -alkyl, C_3 - C_6 -sykloalkyl, C_1 - C_6 -alkoksy, C_1 - C_6 -halogenalkyl, C_1 - C_6 -halogenalkoksy, C_1 - C_6 -alkyl- $N(R^N)_2$, fenyl, benzyl, 4- til 8-leddet heterosyklyl og 5- til 6-leddet heteroaryl; hvor R^1 er bundet til det tilstøtende karbonylet med et karbonatom, og hvor R^1 er eventuelt substituert med én eller to substituenten valgt fra gruppen som består av F, Cl, Br, C_1 - C_6 -alkyl, C_3 - C_6 -sykloalkyl, C_1 - C_6 -alkoksy, C_1 - C_6 -halogenalkyl, C_1 - C_6 -halogenalkoksy, C_1 - C_6 -alkyl- $N(R^N)_2$, hydroksyl, hydroksymetyl, cyano, cyanometyl, cyanoetyl, $C(O)C_1$ - C_6 -alkyl, fenyl, benzyl, CH_2 -(C_3 - C_6 -sykloalkyl), 5- til 6-leddet heteroaryl og CH_2 -(5- til 6-leddet heteroaryl);

hver R^N er uavhengig valgt fra gruppen som består av H, C_1 - C_6 -alkyl, C_3 - C_6 -sykloalkyl, C_1 - C_6 -alkoksy og C_1 - C_6 -halogenalkyl; eller to R^N kan sammen med det tilstøtende N-atomet danne en 4-6-leddet ring; og

A-ringen og B-ringen sammen er valgt fra gruppen som består av:






hvor:

R^2 er valgt fra gruppen som består av C_1 - C_6 -halogenalkyl, C_3 - C_6 -sykloalkyl, C_1 - C_6 -alkoksy, C_1 - C_6 -halogenalkoksy, C_1 - C_6 -tioalkyl, fenyl, benzyl, CH_2 -(C_3 - C_6 -sykloalkyl), CH_2CH_2 -(C_3 - C_6 -sykloalkyl), CH_2 -(4- til 6-leddet heterosyklyl), CH_2CH_2 -(4- til 6-leddet heterosyklyl), 5- til 6-leddet heteroaryl og CH_2 -(5- til 6-leddet heteroaryl); der, når en fenyling er til stede kan den være substituert med 1 til 3 substituenten valgt fra gruppen som består av halogen, C_1 - C_4 -alkyl, C_1 - C_4 -halogenalkyl, C_1 - C_4 -alkoksy, C_1 - C_4 -halogenalkoksy og cyano; og

R^{3a} og R^{3b} er valgt som følger:

- (i) én av R^{3a} og R^{3b} er H, og den andre er valgt fra gruppen som består av D, F, Cl, OH, CN, C_1 - C_4 -alkyl, C_1 - C_4 -halogenalkyl, syklopropyl, C_1 - C_4 -alkoksy og C_1 - C_4 -halogenalkoksy;
- (ii) hver av R^{3a} og R^{3b} er valgt fra gruppen som består av D, F, Cl, OH, CN og metyl, forutsatt at R^{3a} og R^{3b} ikke begge kan være OH eller CN; eller
- (iii) R^{3a} og R^{3b} sammen danner syklopropyl.

2. Forbindelse med formel (I):




eller et farmasøytisk akseptabelt salt derav, hvor:

R^1 er valgt fra gruppen som består av C_1 - C_6 -alkyl, C_3 - C_6 -sykloalkyl, C_1 - C_6 -alkoksy, C_1 - C_6 -halogenalkyl, C_1 - C_6 -halogenalkoksy, C_1 - C_6 -alkyl- $N(R^N)_2$, fenyl, benzyl, 4- til 8-leddet heterosyklyl og 5- til 6-leddet heteroaryl; hvor R^1 er bundet til det tilstøtende karbonylet med et karbonatom, og hvor R^1 er eventuelt

substituert med én eller to substituenten valgt fra gruppen som består av F, Cl, Br, C₁-C₆-alkyl, C₃-C₆-sykloalkyl, C₁-C₆-alkoksy, C₁-C₆-halogenalkyl, C₁-C₆-halogenalkoksy, C₁-C₆-alkyl-N(R^N)₂, hydroksyl, hydroksymetyl, cyano, cyanometyl, cyanoetyl, C(O)C₁-C₆-alkyl, fenyl, benzyl, CH₂-(C₃-C₆-sykloalkyl), 5- til 6-leddet heteroaryl og CH₂-(5- til 6-leddet heteroaryl);

hver R^N er uavhengig valgt fra gruppen som består av H, C₁-C₆-alkyl, C₃-C₆-sykloalkyl, C₁-C₆-alkoksy, og C₁-C₆-halogenalkyl; eller to R^N kan sammen med det tilstøtende N-atomet danne en 4-6-leddet ring; og

A-ringen og B-ringen sammen er valgt fra gruppen som består av:



hvor:

R² er valgt fra gruppen som består av C₁-C₆-halogenalkyl, C₃-C₆-sykloalkyl, C₁-C₆-alkoksy, C₁-C₆-halogenalkoksy, C₁-C₆-tioalkyl, fenyl, benzyl, CH₂-(C₃-C₆-sykloalkyl), CH₂CH₂-(C₃-C₆-sykloalkyl), CH₂-(4- til 6-leddet heterosyklyl), CH₂CH₂-(4- til 6-leddet heterosyklyl), 5- til 6-leddet heteroaryl, og CH₂-(5- til 6-leddet heteroaryl); og når en fenylring er til stede kan den være substituert

med 1 til 3 substituenten valgt fra gruppen som består av halogen, C₁-C₄-alkyl, C₁-C₄-halogenalkyl, C₁-C₄-alkoksy, C₁-C₄-halogenalkoksy og cyano; og


R^{4a} og R^{4b} er valgt som følger:

(i) én av R^{4a} og R^{4b} er H, og den andre er valgt fra gruppen som består av D, F, Cl, OH, CN, C₁-C₄-alkyl, C₁-C₄-halogenalkyl, syklopropyl, C₁-C₄-alkoksy og C₁-C₄-halogenalkoksy; eller


(ii) hver av R^{4a} og R^{4b} er valgt fra gruppen som består av D, F, Cl og metyl.

3. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvor R² er valgt fra gruppen som består av fenyl, monofluorfenyl, difluorfenyl, monoklorfenyl og diklorfenyl.

4. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvor A-ringen og B-ringen sammen er valgt fra gruppen som består av:



og



hvor:

R^{3a} og R^{3b} er valgt som følger:

(i) én av R^{3a} og R^{3b} er H, og den andre er valgt fra gruppen som består av D, F, Cl, OH, CN, C₁-C₄-alkyl, C₁-C₄-halogenalkyl, syklopropyl, C₁-C₄-alkoksy og C₁-C₄-halogenalkoksy;

(ii) hver av R^{3a} og R^{3b} er valgt fra gruppen som består av D, F, Cl, OH, CN og metyl, forutsatt at R^{3a} og R^{3b} ikke begge kan være OH eller CN; eller


(iii) R^{3a} og R^{3b} sammen danner syklopropyl;

hvor R⁵ er valgt fra gruppen som består av H, F, Cl, C₁-C₄-alkyl, C₁-C₄-halogenalkyl, C₁-C₄-alkoksy og C₁-C₄-halogenalkoksy; og

m er 1, 2 eller 3.

5. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvor A-ringen og B-ringen sammen er:

5




hvor:

hver R^5 er valgt fra gruppen som består av H, F, Cl, C_1 - C_4 -alkyl, C_1 - C_4 -halogenalkyl, C_1 - C_4 -alkoksy og C_1 - C_4 -halogenalkoksy; og m er 1, 2 eller 3.

6. Forbindelse ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvor R^2 er valgt fra gruppen som består av fenyl, monofluorfenyl, difluorfenyl, monoklorfenyl og diklorfenyl.

7. Forbindelse ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvor A-ringen og B-ringen sammen er valgt fra gruppen som består av:




hvor:

R^{4a} og R^{4b} er valgt som følger:


(i) én av R^{4a} og R^{4b} er H, og den andre er valgt fra gruppen som består av F, Cl, OH, CN, C_1 - C_4 -alkyl, C_1 - C_4 -halogenalkyl, syklopropyl, C_1 - C_4 -alkoksy og C_1 - C_4 -halogenalkoksy; eller

(ii) hver av R^{4a} og R^{4b} er valgt fra gruppen som består av F, Cl og metyl; hver R^5 er valgt fra gruppen som består av H, F, Cl, C_1 - C_6 -alkyl, C_1 - C_4 -halogenalkyl, C_1 - C_4 -alkoksy og C_1 - C_4 -halogenalkoksy; og m er 1, 2 eller 3.


8. Forbindelse ifølge krav 1 eller krav 2, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er valgt fra gruppen som består av:




((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1R,2R)-2-fluorsyklopropyl)metanon;




((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1S,2S)-2-fluorsyklopropyl)metanon;




((5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1R,2R)-2-fluorsyklopropyl)metanon;




((5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1S,2S)-2-fluorsyklopropyl)metanon;




2-hydroksy-2-metyl-1-[ras.-(SR,7R)-7-fluor-5-fenyl-6,7-dihydro-SH-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




2-hydroksy-2-metyl-1-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




2-fenyl-1-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]etanon;




((5R,7R)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1R,2S)-2-fluorsyklopropyl)metanon;




((5R,7R)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1S,2R)-2-fluorsyklopropyl)metanon;




(7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-[ras.-(1S,2S)-2-fluorsyklopropyl]metanon;




(2,2-difluorsyklopropyl)-(7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




fenyl-[ras.-(5S,7S)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




1-[ras.-(5R,7S)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-[1-(trifluormetyl)syklopropyl]metanon;




(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-(3-metyloksetan-3-yl)metanon;




(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-[ras.-(1S,2R)-2-fluorsyklopropyl]metanon;




syklopropyl-[ras.-(5R,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




3-(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-2,2-dimetyl-3-okso-propannitril;




1-(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-2-hydroksy-2-metyl-propan-1-on;




(ras.-(5S,7S)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-(1-methylsyklopropyl)metanon;




3,3,3-trifluor-1-[ras.-(5R,7R)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




1-[ras.-(5R,6S)-6-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




(ras.-(5S,7S)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-(2-pyridyl)metanon;




syklopropyl-[(5S,7S)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5R,7R)-7-fluor-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopentyl-(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




2,2-dimetyl-1-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




2,2-dimetyl-1-[ras.-(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




(1-metylpirazol-4-yl)-[ras.-(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




(1-metylpirazol-4-yl)-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-(2-tienyl)metanon;




syklopropyl-(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




syklobutyl-[ras.-(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




1-(7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-2,2-dimetyl-propan-1-on;




1-(7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-2-metyl-propan-1-on;




1-[ras.-(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




1-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on




(1-metylpirazol-4-yl)-[ras.-(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




1-[ras.-(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




1-[ras.-(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]etanon;




((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1R,2S)-2-fluorsyklopropyl)metanon;




((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1S,2R)-2-fluorsyklopropyl)metanon;




(1-fluorsyklopropyl)-(ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




(3-metyloksetan-3-yl)-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




(3-metyloksetan-3-yl)-[(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




3-oksabisyklo[3.1.0]heksan-6-yl-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




oksetan-3-yl-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[1-(hydroksymetyl)syklopropyl]-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;



[(1R)-2,2-difluorsyklopropyl]-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(1S)-2,2-difluorsyklopropyl]-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon; og




(1-fluorsyklopropyl)-[(SS,7S)-7-fluor-5-fenyl-6,7-dihydro-SH-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;


eller gruppen som består av:




syklopropyl-[(5S,7S)-7-fluor-5-(2-fluorfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




(3,3-difluorsyklobutyl)-[(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(1S,2R)-2-fluorsyklopropyl]-[(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(5S)-7,7-difluor-5-fenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-2-yl]-[(1S,2R)-2-fluorsyklopropyl]metanon;




[(5S)-7,7-difluor-5-fenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-2-yl]-[(1R,2S)-2-fluorsyklopropyl]metanon;




syklopropyl-[(5S)-7,7-difluor-5-fenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(1R,2S)-2-fluorsyklopropyl]-[(5R,7R)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




(2,2-difluorspiro[2.3]heksan-5-yl)-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[1-(hydroksymetyl)syklopropyl]-[(SS,7S)-7-fluor-5-fenyl-6,7-dihydro-SH-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




(3,3-difluorsyklobutyl)-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[2-(2-pyridyl)syklopropyl]-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(1S,2S)-2-metylsyklopropyl]metanon;




[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-spiro[2.3]heksan-5-yl-metanon;




syklopropyl-[ras.-(4S,6S)-4-fluor-6-fenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]metanon;




[1-(fluormetyl)syklopropyl]-[(SS,7S)-7-fluor-5-fenyl-6,7-dihydro-SH-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




(3,3-difluor-6-bisyklo[3.1.0]heksanyl)-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[2-(trifluormetyl)syklopropyl]metanon;




(6,6-difluor-3-bisyklo[3.1.0]heksanyl)-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




2-[1-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-karbonylsyklopropyl]acetonitril;




syklopropyl-[(5S,7S)-7-metoksy-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-7-fluor-5-(4-fluorfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




2-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-karbonyl]-syklopropankarbonitril;




syklopropyl-[(5S,7S)-7-hidroksy-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7R)-7-hydroksy-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(SS,7S)-7-fluor-5-fenyl-6,7-dihydro-SH-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[(1S,2S)-2-metylsyklopropyl]metanon;




[(1R,2S)-2-fluorsyklopropyl]-[(SS,7S)-7-fluor-5-(2-fluorfenyl)-6,7-dihydro-SH-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[(1R,2R)-2-metylsyklopropyl]metanon;




syklopropyl-[(5S,7S)-5-(2,6-difluorfenyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




1-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-karbonyl]syklopropankarbonitril;




[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-spiro[2.2]pentan-2-yl-metanon;




[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-spiro[2.3]heksan-2-yl-metanon;




[1-(2-pyridyl)syklopropyl]-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




(1-syklopropylsyklopropyl)-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-5-(2-klorfenyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-5-(2,5-difluorfenyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-7-fluor-5-(2,3,6-trifluorfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-7-deuterio-7-fluor-5-fenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[(1S,2R)-2-fluorsyklopropyl]-[(5S,7S)-7-fluor-5-(2-fluorfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




ras.-(1R,2R)-2-[(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-karbonyl]syklopropankarbonitril;




syklopropyl-[(5S,7S)-5-(2,3-difluorfenyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-7-fluor-5-(2,3,5-trifluorfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(4S,6S)-4-fluor-6-fenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]metanon;




syklopropyl-[(5S,7S)-5-syklopropyl-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-7-deuterio-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[ras.-(5S,7S)-5-(1,1-difluorpropyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5R,7S)-5-(syklopropylmetyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S)-7,7-dideuterio-5-fenyl-5,6-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5R,7R)-7-klor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-7-klor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7R)-7-klor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[ras.-(5S,7S)-5-(3-klor-2-pyridyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[ras.-(5S,7S)-7-klor-7-deuterio-5-fenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[ras.-(5S,7R)-7-klor-7-deuterio-5-fenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-5-(1,1-difluoropropyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[ras.-(SS,7S)-5-(1,1-difluoretyl)-7-fluor-6,7-dihydro-SH-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(5S,7S)-5-(3-klor-2-pyridyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




2-[(5S,7S)-2-(syklopropankarbonyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitril;




(1-etylsyklopropyl)-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-tetrahydropyran-4-yl-metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-tetrahydropyran-3-yl-metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(2R)-pyrrolidin-2-yl]metanon;




(2-metyltetrahydrofuran-2-yl)-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-tetrahydrofuran-3-yl-metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(3S)-tetrahydrofuran-3-yl]metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(3R)-tetrahydrofuran-3-yl]metanon;




3-metoksy-2,2-dimetyl-1-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




ras.-(2S)-3,3,3-trifluor-2-hydroksy-1-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-on;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(3R)-3-metyltetrahydrofuran-3-yl]metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(3S)-3-metyltetrahydrofuran-3-yl]metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(1R,2R,4S)-7-oksabisyklo[2.2.1]heptan-2-yl]metanon;




((1S,2R,4R)-7-oksabisyklo[2.2.1]heptan-2-yl)((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




((1*R*,2*S*,4*S*)-7-oksabisyklo[2.2.1]heptan-2-yl)((5*S*,7*S*)-7-fluor-5-fenyl-6,7-dihydro-5*H*-pyrrolo[1,2-*b*][1,2,4]triazol-2-yl)metanon;




1-[ras.-(5*S*,7*S*)-7-fluor-5-fenyl-6,7-dihydro-5*H*-pyrrolo[1,2-*b*][1,2,4]triazol-2-yl]-2-(trifluormetoksy)etanon;




[ras.-(5*S*,7*S*)-7-fluor-5-fenyl-6,7-dihydro-5*H*-pyrrolo[1,2-*b*][1,2,4]triazol-2-yl]-[ras.-(1*R*,5*R*)-3-oksabisyklo[3.1.0]heksan-1-yl]metanon;




[ras.-(5*S*,7*S*)-7-fluor-5-fenyl-6,7-dihydro-5*H*-pyrrolo[1,2-*b*][1,2,4]triazol-2-yl]-[ras.-(1*S*,5*S*)-3-oksabisyklo[3.1.0]heksan-1-yl]metanon;




syklopropyl((5*S*,7*R*)-7-hidroksy-5-(*o*-tolyl)-6,7-dihydro-5*H*-pyrrolo[1,2-*b*][1,2,4]triazol-2-yl)metanon;




syklopropyl-[(ras.-(5S,7R)-7-fluor-5-(o-tolyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl-[(ras.-(5S,7S)-7-fluor-5-(o-tolyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;




syklopropyl((5S,7S)-7-fluor-5-(3-fluorpyridin-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




syklopropyl((5S,7R)-7-fluor-5-(3-fluorpyridin-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




syklopropyl((5S,7S)-7-fluor-5-(1-metyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




syklopropyl(7-fluor-5-(5-metylisoksazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




((5S,7S)-5-(4-klor-1-metyl-1H-pyrazol-3-yl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)(syklopropyl)metanon;




((5S,7R)-5-(4-klor-1-metyl-1H-pyrazol-3-yl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)(syklopropyl)metanon;




syklopropyl((5S,7S)-7-fluor-5-(3-metoksyfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




syklopropyl((5S,7S)-7-fluor-5-(3-fluor-5-(trifluormetyl)fenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;




syklopropyl((4S,6S)-4-fluor-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)metanon;




[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(1S,2S)-2-(trifluormetyl)syklopropyl]metanon;



[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(1R,2R)-2-(trifluormetyl)syklopropyl]metanon;



[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(2S)-spiro[2.2]pentan-2-yl]metanon; og



[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-[ras.-(2R)-spiro[2.2]pentan-2-yl]metanon.

9. Forbindelse ifølge krav 8, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er valgt fra gruppen som består av:

((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1R,2R)-2-fluorsyklopropyl)metanon;

fenyl-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;
 (ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-(1-metylsyklopropyl)metanon;
 syklopropyl((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon;
 [(1R,2S)-2-fluorsyklopropyl]-[(5S,7S)-7-fluor-5-(2-fluorfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;
 syklopropyl-[(5S,7S)-5-(2,6-difluorfenyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;
 syklopropyl-[(5S,7S)-5-(2-klorfenyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon;
 syklopropyl-[(5S,7S)-7-klor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon; og
 syklopropyl((5S,7S)-7-fluor-5-(3-metoksyfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon.

10. Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er ((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)((1R,2R)-2-fluorsyklopropyl)metanon.

11. Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er fenyl-[ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon.

12. Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er (ras.-(5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-(1-metylsyklopropyl)metanon.

13. Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er syklopropyl((5S,7S)-7-fluor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon.

14. Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er [(1R,2S)-2-fluorsyklopropyl]-[(5S,7S)-7-fluor-5-(2-fluorfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon.

15. Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er syklopropyl-[(5S,7S)-5-(2,6-difluorfenyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon.

- 16.** Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er syklopropyl-[(5S,7S)-5-(2-klorfenyl)-7-fluor-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon.
- 17.** Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er syklopropyl-[(5S,7S)-7-klor-5-fenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]metanon.
- 18.** Forbindelse ifølge krav 9, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen er syklopropyl((5S,7S)-7-fluor-5-(3-metoksyfenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)metanon.
- 19.** Forbindelse ifølge krav 1 eller krav 2, eller et farmasøytisk akseptabelt salt derav, hvor den valgte forbindelsen er en forbindelse som har en RIP1-kinasehemmende aktivitet K_i på mindre enn 100 nM.
- 20.** Farmasøytisk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av kravene 1–19, eller et farmasøytisk akseptabelt salt derav, og en terapeutisk inert bærer.
- 21.** Forbindelse ifølge et hvilket som helst av kravene 1–19, eller et farmasøytisk akseptabelt salt derav, for anvendelse som et terapeutisk aktivt stoff.
- 22.** Forbindelse ifølge et hvilket som helst av kravene 1–19, eller et farmasøytisk akseptabelt salt derav, for anvendelse i behandlingen av en sykdom eller lidelse valgt fra gruppen som består av Parkinsons sykdom, demens med Lewy-legemer, multisystematrofi, Parkinson pluss-syndrom, tauopati, Alzheimers sykdom, frontotemporal demens, amyotrofisk lateral sklerose, spinal muskelatrofi, primær lateral sklerose, Huntingtons sykdom, iskemi, hjerneslag, intrakraniell blødning, hjerneblødning, muskeldystrofi, progressiv muskelatrofi, pseudobulbær parese, progressiv bulbær parese, spinal muskelatrofi, arvelig muskelatrofi, perifer nevropati, progressiv supranukleær parese, kortikobasal degenerasjon og demyeliniserende sykdom.
- 23.** Forbindelse ifølge et hvilket som helst av kravene 1–19, eller et farmasøytisk akseptabelt salt derav, for anvendelse i behandlingen av en sykdom eller lidelse valgt fra gruppen som består av inflammatorisk tarmsykdom, Crohns sykdom, ulcerøs kolitt, glaukom, psoriasis, psoriasisartritt, revmatoid artritt, spondyloartritt, juvenil idiopatisk artritt og slitasjegikt.

24. Forbindelsen for anvendelse ifølge krav 22 eller 23, hvor sykdommen eller lidelsen er valgt fra gruppen som består av Alzheimers sykdom, multippel sklerose, Parkinsons sykdom, amyotrofisk lateral sklerose, Huntingtons sykdom, spinal muskelatrofi, en inflammatorisk tarmsykdom, Crohns sykdom, ulcerøs kolitt, psoriasis, psoriasisartritt, revmatoid artritt, spondyloartritt og juvenil idiopatisk artritt.